Patents by Inventor Stanislas MONDOT

Stanislas MONDOT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12276000
    Abstract: The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas catoniae compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas catoniae in a biological sample obtained from said subject.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: April 15, 2025
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST, UNIVERSITE BRETAGNE OCCIDENTALE, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNMENT, ETABLISSEMENT FRANCAIS DU SANG (EFS)
    Inventors: Geneviève Hery-Arnaud, Jérôme Mounier, Charles-Antoine Guilloux, Patricia Lepage, Stanislas Mondot, Marlène Keravec
  • Patent number: 12077827
    Abstract: The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas genus bacteria in a biological sample obtained from said subject.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: September 3, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE BRETAGNE OCCIDENTALE, ETABLISSEMENT FRANCAIS DU SANG (EFS), CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'EVIRONNEMENT
    Inventors: Geneviève Hery-Arnaud, Jérôme Mounier, Marlène Keravec, Stanislas Mondot, Patricia Lepage, Charles-Antoine Guilloux
  • Publication number: 20210017584
    Abstract: The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas catoniae compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas catoniae in a biological sample obtained from said subject.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 21, 2021
    Inventors: Geneviève HERY-ARNAUD, Jérôme MOUNIER, Charles-Antoine GUILLOUX, Patricia LEPAGE, Stanislas MONDOT, Marlène KERAVEC
  • Publication number: 20200283829
    Abstract: The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas genus bacteria in a biological sample obtained from said subject.
    Type: Application
    Filed: September 28, 2018
    Publication date: September 10, 2020
    Inventors: Geneviève HERY-ARNAUD, Jérôme MOUNIER, Marlène KERAVEC, Stanislas MONDOT, Patricia LEPAGE, Charles-Antoine GUILLOUX